Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.63 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.60 |
| ▸ | BRAF | P15056 | 7/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 3/20 | 0.58 |
| ▸ | EGFR | P00533 | 6/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22018088 | 0.92 | TMPRSS2 (0.61) | KITTMPRSS2FGFR1BRAFKDR | |
| SCHEMBL22017590 | 0.90 | TMPRSS2 (0.68) | KITTMPRSS2BRAFABL1EGFR | |
| SCHEMBL22017401 | 0.90 | TMPRSS2 (0.68) | KITTMPRSS2BRAFABL1EGFR | |
| SCHEMBL22017239 | 0.90 | TMPRSS2 (0.70) | KITTMPRSS2BRAFABL1EGFR | |
| SCHEMBL22018089 | 0.90 | TMPRSS2 (0.68) | KITTMPRSS2BRAFABL1EGFR | |
| SCHEMBL22017757 | 0.89 | TMPRSS2 (0.67) | KITTMPRSS2BRAFABL1EGFR | |
| SCHEMBL22017232 | 0.89 | KIT (0.66) | KITTMPRSS2BRAFABL1EGFR | |
| SCHEMBL22017407 | 0.88 | TMPRSS2 (0.66) | KITTMPRSS2BRAFABL1EGFR | |
| SCHEMBL19500739 | 0.86 | KIT (0.78) | KITFGFR1BRAFABL1EGFR | |
| SCHEMBL15847156 | 0.85 | KIT (0.71) | KITBRAFABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020098710-A1 | SUBSTITUTED BIS-ARYL AMIDE COMPOUND AND PREPARATION METHOD AND APPLICATION THEREFOR | 中国医学科学院医药生物技术研究所 | 2020-05-22 | — | — | WO | disclosed |